Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.


  • Letter of Intent Due Date(s): February 09, 2022 and September 7, 2022
  • Application Due Date(s): March 9, 2022 and October 7, 2022

​RFA-DK-21-012 Expiration Date October 08, 2022

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. 

Amount Description

Budgets up to $300,000 total costs per project for Phase I and up to $2,000,000 total costs per project for Phase II may be requested.

    Funding Type





    Engineering and Physical Sciences
    Environmental & Life Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    October 7, 2022